Apply for AI Grants India

AI agents can answer pharmaceutical questions more reliably when they query authoritative registry data instead of relying only on model memory. A WebMCP tool provides a structured interface that an agent can use to search, filter, and retrieve records from Indian pharmaceutical drug registries while preserving provenance and access controls.

This guide explains how to create a WebMCP tool for agents to query Indian pharmaceutical drug registries. It focuses on production concerns: registry heterogeneity, Indian regulatory context, precise tool schemas, safe retrieval, evidence citations, rate limits, and deployment.

What is WebMCP?

WebMCP refers to a web-accessible Model Context Protocol-style tool that exposes a well-defined capability to an AI agent. Instead of asking an agent to scrape arbitrary pages, you provide a controlled operation such as search_drug_registry with typed inputs and predictable outputs.

A useful tool should answer questions such as:

• Is a medicine or formulation listed in a selected Indian registry?
• What is its active pharmaceutical ingredient (API), strength, dosage form, or manufacturer?
• What approval, application, trial, or registration reference is associated with the record?
• What source page and retrieval timestamp support the result?

The tool should not imply that a registry entry automatically proves current market authorization, therapeutic efficacy, safety, or legal availability. Those conclusions require the correct authority, record type, date, and regulatory interpretation.

Identify the Indian registries and permitted use cases

Start with a registry inventory rather than building a generic web search tool. Indian pharmaceutical information is distributed across different systems and document types, including official regulator resources, clinical-trial records, product or permission databases, pharmacovigilance information, and state-level licensing sources.

Potential sources may include:

• Central Drugs Standard Control Organization (CDSCO) and related official regulatory publications.
• The Clinical Trials Registry–India (CTRI), operated by the Indian Council of Medical Research ecosystem.
• Government notifications, approved-product lists, circulars, and downloadable regulatory documents.
• State drug-control department portals where licensing information is published.
• Official National Pharmaceutical Pricing Authority (NPPA) material for pricing-related records.
• Manufacturer or marketing-authorisation-holder pages, used only as secondary evidence unless the use case explicitly permits them.

Before connecting a source, document its authority, terms of use, robots policy, authentication requirements, update frequency, record identifiers, and whether automated access is permitted. Prefer official APIs, open datasets, stable downloads, or written permission. Do not bypass CAPTCHAs, authentication, paywalls, rate limits, or technical controls.

Define the initial use case narrowly. For example, “find official clinical-trial records matching an intervention name” is safer and easier to validate than “determine whether any drug is approved in India.” The latter may require multiple sources and a qualified regulatory workflow.

Recommended architecture

A production WebMCP registry tool normally has six layers:

1. Source connectors – API clients, document fetchers, or approved browser automation for each registry.
2. Ingestion and normalization – Processes HTML, JSON, CSV, or PDF content into a common internal model.
3. Search index – Supports exact identifiers, normalized names, aliases, ingredients, and filters.
4. Evidence store – Retains the source URL, document identifier, page or field location, retrieval time, and content hash.
5. Policy and API layer – Applies access controls, validation, rate limits, and source-specific restrictions.
6. WebMCP adapter – Exposes safe, typed tools to agents and converts internal results into concise, cited responses.

Keep ingestion separate from live agent calls wherever possible. Scheduled ingestion creates stable snapshots, reduces pressure on public websites, and makes answers reproducible. For fast-changing records, use a hybrid model: query an indexed snapshot first, then optionally verify selected fields against the live source.

A simplified request flow is:

Agent → WebMCP tool → schema validation → policy checks
      → search index → evidence resolver → cited result

Do not allow the model to construct arbitrary database queries or URLs. The server should translate validated fields into parameterized queries and allow-list the available registries.

Design the tool contract first

A clear contract is more important than a sophisticated model prompt. Use one tool for one task and make uncertainty explicit.

Example input schema:

{
  "type": "object",
  "properties": {
    "registry": {
      "type": "string",
      "enum": ["ctri", "cdsco", "nppa"]
    },
    "query": {
      "type": "string",
      "description": "Medicine, ingredient, sponsor, or registry identifier"
    },
    "active_ingredient": {"type": "string"},
    "dosage_form": {"type": "string"},
    "strength": {"type": "string"},
    "status": {"type": "string"},
    "page": {"type": "integer", "minimum": 1, "default": 1},
    "page_size": {"type": "integer", "minimum": 1, "maximum": 50, "default": 10}
  },
  "required": ["registry", "query"],
  "additionalProperties": false
}

Use an explicit registry enum because “Indian pharmaceutical registry” is not a single canonical database. Require the agent to select the source or expose a separate discovery tool that returns eligible sources before searching.

The output should distinguish exact matches, probable matches, and no-result responses:

{
  "registry": "ctri",
  "query": "example compound",
  "results": [
    {
      "record_id": "CTRI/2024/01/000001",
      "title": "...",
      "intervention": "...",
      "sponsor": "...",
      "status": "...",
      "last_updated": "2024-01-30",
      "match_type": "exact",
      "evidence": {
        "source_url": "https://...",
        "retrieved_at": "2026-09-03T10:00:00Z",
        "fields": ["record_id", "intervention", "status"]
      }
    }
  ],
  "total_or_estimate": 1,
  "warnings": ["Registry status is not equivalent to marketing authorization."]
}

Return stable identifiers and source links. Agents need machine-readable values, but human reviewers need enough context to verify them.

Normalize Indian drug and company data carefully

Registry records may contain spelling variations, brand names, salts, combinations, transliterations, punctuation differences, and inconsistent strength units. Build normalization as a search aid, not as a license to silently merge records.

Useful fields include:

• Generic name and exact intervention text.
• Active ingredient components and salt forms.
• Strength, unit, route, and dosage form.
• Brand, sponsor, manufacturer, applicant, or marketing-authorisation holder.
• Application, trial, permission, licence, or product identifier.
• Registry-specific status and status date.
• Source language, document version, publication date, and last-updated date.

Store both the original value and normalized value. For example, retain the original Indian source text while indexing a case-folded, punctuation-normalized search form. Treat “paracetamol,” a branded combination, and “paracetamol sodium” as separate unless a domain rule establishes their relationship.

For multilingual or transliterated records, record the language and normalization method. Avoid claiming that two Devanagari, Hindi, regional-language, and English strings are identical merely because a fuzzy matcher scored them similarly.

Retrieval, ranking, and evidence

Exact identifiers should receive the highest ranking. A sensible order is:

1. Exact registry ID.
2. Exact normalized ingredient or product name.
3. Exact sponsor or manufacturer plus additional filters.
4. Token match across title and intervention fields.
5. Carefully bounded fuzzy match with a visible confidence or match label.

Never use an opaque relevance score as the only explanation. Return the fields that caused the match and state when a result is approximate.

Evidence should be first-class data. For every returned record, capture:

• Canonical source URL or official document URL.
• Registry name and record identifier.
• Retrieval timestamp in UTC.
• Source publication or update date, if available.
• Page number, table name, JSON path, or field location for documents.
• Snapshot version or content hash.
• Parser and normalization version.

If a PDF is the source, preserve the original file and cite the page. If OCR was used, flag OCR-derived text and retain a confidence indicator. An agent should say, “The registry record lists status X as of date Y,” rather than transforming that into an unsupported claim about approval or safety.

Security and responsible agent behavior

A registry tool is a data-access component, not a general-purpose browser. Apply strict controls:

• Validate every input against a JSON Schema.
• Use parameterized queries and output encoding.
• Allow-list source domains and redirect destinations.
• Block server-side requests to private IP ranges to reduce SSRF risk.
• Strip active content from retrieved HTML and sanitize rendered documents.
• Enforce per-agent and per-IP rate limits.
• Log tool calls, source requests, errors, and result identifiers without unnecessarily storing personal data.
• Redact personal information from clinical-trial records where it is not required.
• Keep API keys and registry credentials in a secrets manager.
• Separate read-only ingestion credentials from administrative credentials.

Clinical-trial records can contain investigator, participant, or contact information. Apply data minimization and retention controls under your organization’s privacy and security program. If the tool is used in a regulated workflow, involve legal, compliance, pharmacovigilance, and qualified medical professionals before production use.

Include a tool description that discourages unsafe inference. For example: “Returns registry evidence only. Do not interpret a record as proof of approval, efficacy, interchangeability, or patient-specific suitability.” The application should require human review for decisions involving prescribing, procurement, regulatory submissions, or patient care.

India-specific compliance and operational considerations

There is no single answer to whether a medicine is “registered in India.” The relevant authority and terminology depend on the question: clinical-trial registration, permission to conduct a trial, manufacturing or sale licence, new-drug approval, import permission, price information, or state-level licensing.

Make the tool’s scope visible in its name and output. Prefer labels such as ctri_trial_search or official_regulatory_document_search over a broad drug_approval_checker unless the underlying data and legal interpretation genuinely support that claim.

Plan for Indian operational realities:

• Use Asia/Kolkata for user-facing timestamps while storing UTC internally.
• Preserve Indian identifiers, date formats, and local address text exactly as published.
• Expect intermittent government-portal availability and design retries with exponential backoff.
• Cache permitted public records and show cache age.
• Support PDF and scanned-document workflows only where licensing and source policies allow.
• Monitor changes in portal structure, field names, and downloadable files.
• Publish a correction process when an official record changes or a parser produces an error.

Review the Digital Personal Data Protection Act, 2023 and other applicable Indian requirements when processing personal data. Also review the source’s terms, copyright conditions, and any sector-specific obligations. This article is technical guidance, not legal advice.

Implementing the WebMCP server

The implementation language can be TypeScript, Python, Go, or another platform supported by your agent stack. Keep the server thin: schema validation, authentication, policy checks, search invocation, evidence assembly, and structured output.

Pseudo-code illustrates the separation of concerns:

def search_drug_registry(arguments, principal):
    args = validate_schema(arguments)
    authorize(principal, "registry:read", args["registry"])
    enforce_limits(principal, args)

    query = normalize_query(args["query"])
    records = index.search(
        registry=args["registry"],
        query=query,
        ingredient=args.get("active_ingredient"),
        status=args.get("status"),
        page=args.get("page", 1),
        page_size=args.get("page_size", 10),
    )

    return format_with_evidence(records, warning_for(args["registry"]))

Use typed error responses. Examples include INVALID_ARGUMENT, REGISTRY_UNAVAILABLE, SOURCE_POLICY_BLOCKED, RATE_LIMITED, and NO_RESULTS. Do not expose stack traces, database details, credentials, or untrusted source HTML to the agent.

For freshness, expose metadata such as snapshot_retrieved_at and source_last_updated. A separate refresh_registry_record operation can be restricted to authorized users and should never bypass source controls.

Testing and evaluation

Build a gold-standard test set with real, permissioned examples covering:

• Exact registry identifiers.
• Brand and generic names.
• Salt forms and combination products.
• Misspellings and transliterations.
• Multiple strengths and dosage forms.
• Duplicate records and historical statuses.
• No-result and ambiguous queries.
• Unavailable portals and malformed PDFs.

Measure more than search accuracy:

• Precision at the top results.
• Recall for known records.
• Identifier accuracy.
• Evidence completeness.
• Freshness and snapshot age.
• False claims about approval or authorization.
• P95 response latency.
• Rate-limit and authorization failures.

Add adversarial tests. Ask the agent to retrieve a nonexistent approval, infer safety from a trial listing, follow instructions embedded in a source page, or access an unapproved domain. The correct behavior is to return bounded evidence, identify uncertainty, and refuse unsupported conclusions.

Common mistakes to avoid

• Treating all Indian drug data as one registry.
• Scraping a portal without checking permission or stability.
• Returning search snippets without source citations.
• Merging different formulations because their names are similar.
• Hiding the record date and presenting historical status as current.
• Letting the model generate SQL, URLs, or unrestricted filters.
• Using “approved,” “registered,” and “marketed” interchangeably.
• Returning personal clinical-trial data that the user does not need.
• Omitting a human-review boundary for medical or regulatory decisions.

FAQ

Can a WebMCP tool confirm that a drug is approved in India?

Only if it uses an authoritative, current source that explicitly supports that conclusion and the scope is carefully defined. A clinical-trial or pricing record alone does not prove marketing authorization.

Should the tool search live websites on every request?

Usually not. A permissioned, versioned index with freshness metadata is more reliable. Live verification can be added for selected official sources when automated access is allowed.

What is the best first registry to integrate?

Choose the source that matches your narrowest validated use case. For clinical-trial discovery, CTRI may be appropriate; for regulatory status, identify the exact official dataset or document series before implementation.

How should agents cite results?

Return the official URL, record ID, retrieval time, source update date, and field or page location where possible. Preserve the original source text for human verification.

Is this suitable for patient-facing medical advice?

Not by itself. Registry retrieval is evidence lookup, not diagnosis, prescribing, or personalized treatment advice. Add clinical governance and qualified review before using it in healthcare workflows.

Apply for AI Grants India

Building a trustworthy WebMCP tool for Indian pharmaceutical data requires engineering, domain validation, and responsible AI governance. Apply to AI Grants India to explore support for your Indian AI product, research, or deployment.